Skip to main content
Erschienen in: Drug Safety 3/2018

01.03.2018 | Original Research Article

Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System

verfasst von: Jae Min, Vicki Osborne, Allison Kowalski, Mattia Prosperi

Erschienen in: Drug Safety | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

One-third of adults in the USA experience chronic pain and use a variety of painkillers, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids. However, some serious adverse events (AEs), such as cardiovascular incidents, overdose, and death, have been found to be related to painkillers.

Methods

We used 2015 and 2016 AE reports from the US FDA’s Adverse Events Reporting System (FAERS) to conduct exploratory analysis on the demographics of those who reported painkiller-related AEs, examine the AEs most commonly associated with different types of painkillers, and identify potential safety signals. Summary descriptive statistics and proportional reporting ratios (PRRs) were performed.

Results

Out of over 2 million reports submitted to FAERS in 2015 and 2016, a total of 64,354 AE reports were associated with painkillers. Reports of opioid-associated AEs were more likely to be from males or younger patients (mean age 47.6 years). The highest numbers of AEs were reported for NSAID and opioid use, and the most commonly found AEs were related to drug ineffectiveness, administration issues, abuse, and overdose. Death was reported in 20.0% of the reports, and serious adverse reactions, including death, were reported in 67.0%; both adverse outcomes were highest among patients using opioids or combinations of painkillers and were associated with PRRs of 2.12 and 1.87, respectively.

Conclusions

This study examined the AEs most commonly associated with varying classes of painkillers by mining the FAERS database. Our results and methods are relevant for future secondary analyses of big data and for understanding adverse outcomes related to painkillers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
4.
Zurück zum Zitat Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42:27–38.CrossRefPubMed Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther. 2017;42:27–38.CrossRefPubMed
5.
Zurück zum Zitat Varga Z, Rafay ali Sabzwari S, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 2017;9:e1144.PubMedPubMedCentral Varga Z, Rafay ali Sabzwari S, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 2017;9:e1144.PubMedPubMedCentral
6.
Zurück zum Zitat Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32:1491–502.CrossRefPubMed Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32:1491–502.CrossRefPubMed
7.
Zurück zum Zitat Næsdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 2006;29:119–32.CrossRefPubMed Næsdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 2006;29:119–32.CrossRefPubMed
8.
Zurück zum Zitat Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22:383–90.CrossRefPubMed Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22:383–90.CrossRefPubMed
9.
Zurück zum Zitat Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm Drug Res. 2014;71:11–23. Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm Drug Res. 2014;71:11–23.
10.
Zurück zum Zitat Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (paracetamol)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15:398–405.CrossRefPubMed Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (paracetamol)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15:398–405.CrossRefPubMed
11.
Zurück zum Zitat Ghelardini C, Di Cesare Mannelli L, Bianchi E. The pharmacological basis of opioids. Clin Cases Miner Bone Metab. 2015;12:219–21.PubMedPubMedCentral Ghelardini C, Di Cesare Mannelli L, Bianchi E. The pharmacological basis of opioids. Clin Cases Miner Bone Metab. 2015;12:219–21.PubMedPubMedCentral
13.
Zurück zum Zitat Garg RK, Fulton-kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among medicaid patients. Med Care. 2017;55:661–8.CrossRefPubMed Garg RK, Fulton-kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among medicaid patients. Med Care. 2017;55:661–8.CrossRefPubMed
14.
Zurück zum Zitat Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.CrossRefPubMedPubMedCentral Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, et al. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016;7:131–41.CrossRefPubMedPubMedCentral Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, et al. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016;7:131–41.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277:307–11.CrossRefPubMed Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277:307–11.CrossRefPubMed
23.
Metadaten
Titel
Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System
verfasst von
Jae Min
Vicki Osborne
Allison Kowalski
Mattia Prosperi
Publikationsdatum
01.03.2018
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 3/2018
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-017-0611-5

Weitere Artikel der Ausgabe 3/2018

Drug Safety 3/2018 Zur Ausgabe